ALNY
Alnylam Pharmaceuticals Inc

4,401
Mkt Cap
$51.72B
Volume
167,011.00
52W High
$495.55
52W Low
$205.87
PE Ratio
1,628.54
ALNY Fundamentals
Price
$392.96
Prev Close
$391.50
Open
$391.11
50D MA
$451.30
Beta
0.89
Avg. Volume
973,283.42
EPS (Annual)
-$2.18
P/B
220.60
Rev/Employee
$1.01M
Loading...
Loading...
News
all
press releases
Liontrust Investment Partners LLP Cuts Position in Alnylam Pharmaceuticals, Inc. $ALNY
Liontrust Investment Partners LLP trimmed its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 32.4% in the second quarter, according to its most recent disclosure...
MarketBeat·1d ago
News Placeholder
More News
News Placeholder
Holocene Advisors LP Invests $194.62 Million in Alnylam Pharmaceuticals, Inc. $ALNY
Holocene Advisors LP bought a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities...
MarketBeat·2d ago
News Placeholder
China Universal Asset Management Co. Ltd. Trims Position in Alnylam Pharmaceuticals, Inc. $ALNY
China Universal Asset Management Co. Ltd. reduced its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 10.2% in the 2nd quarter, according to its most recent filing with the...
MarketBeat·2d ago
News Placeholder
Gilder Gagnon Howe & Co. LLC Sells 8,487 Shares of Alnylam Pharmaceuticals, Inc. $ALNY
Gilder Gagnon Howe & Co. LLC reduced its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 2.5% during the 2nd quarter, according to its most recent filing with the Securities...
MarketBeat·3d ago
News Placeholder
Eventide Asset Management LLC Sells 40,548 Shares of Alnylam Pharmaceuticals, Inc. $ALNY
Eventide Asset Management LLC lowered its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 24.4% in the 2nd quarter, according to its most recent 13F filing with the...
MarketBeat·3d ago
News Placeholder
Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Bellevue Group AG
Bellevue Group AG cut its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 11.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange...
MarketBeat·3d ago
News Placeholder
Implied Volatility Surging for Alnylam Pharmaceuticals Stock Options
Investors need to pay close attention to ALNY stock based on the movements in the options market lately.
Zacks·4d ago
News Placeholder
Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $508.00
Stifel Nicolaus increased their price target on Alnylam Pharmaceuticals from $495.00 to $508.00 and gave the stock a "buy" rating in a report on Thursday...
MarketBeat·5d ago
News Placeholder
WINTON GROUP Ltd Makes New Investment in Alnylam Pharmaceuticals, Inc. $ALNY
WINTON GROUP Ltd bought a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) during the second quarter, according to the company in its most recent disclosure with the SEC. The...
MarketBeat·5d ago
News Placeholder
Alnylam Announces Partial Repurchase of 1.00% Convertible Senior Notes Due 2027
Alnylam Pharmaceuticals, Inc. (Alnylam) (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has entered into separate, privately negotiated repurchase agreements with...
Business Wire·5d ago
<
1
2
...
>

Latest ALNY News

View

Advertisement|Remove ads.

Advertisement|Remove ads.